Felip E, Altorki N, Zhou C, Vallieres E, et al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Ann Oncol 2023 Jul 17:S0923-7534(23)00764-0. doi: 10.1016/j.annonc.2023.
PMID: 37467930